Conotoxin Peptide Analog Human Receptor Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current α-conotoxin peptides, such as RgIA, exhibit significant potency differences between rat and human α9α10 nicotinic acetylcholine receptors, limiting their effectiveness in human clinical applications, and existing analogs face challenges in achieving optimal binding and stability.
Innovation Solution
Design and optimization of analog conotoxin peptides through site-directed mutagenesis and structural modifications, including substitutions like Arg to citrulline, Tyr to mono-iodo-Tyr, and cysteine to selenocysteine, to enhance binding affinity and stability, resulting in peptides like Analog 2 and Analog 4, which demonstrate significantly improved potency and stability on human receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If α-conotoxin peptides like RgIA are used to block human α9α10 nAChR, then some blocking activity is achieved, but the potency is insufficient compared to rat receptors
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (1, 2, 3, 9, 10, 13) of the RgIA peptide sequence. These substitutions (e.g., Arg to Cit, Tyr to mono-iodo-Tyr, Cys to Sec) alter the peptide's binding parameters to human α9α10 nAChR, transforming it from a low-potency blocker to a high-potency antagonist with IC50 values as low as 8 nM.
2Reliability
If analog conotoxin peptides are designed to improve binding affinity to human receptors, then potency increases, but structural complexity and synthesis difficulty increase
Solution Approach 1:
The patent applies local quality by making targeted substitutions at specific local positions (1, 2, 3, 9, 10, 13) rather than throughout the entire peptide. Each substitution is designed to improve binding at that specific location while preserving the overall peptide structure and disulfide bond framework, thus achieving high affinity without excessive global complexity.
Solution Approach 2:
The patent creates peptides with universal applicability by designing analogs that maintain >90% sequence identity to RgIA while achieving improved human receptor affinity. The conserved disulfide bond pattern (C1-C3, C2-C4) and core sequence provide a universal scaffold that can be systematically optimized for different therapeutic applications.
3Ease of manufacture
If conventional amino acid sequences are used, then synthesis is straightforward, but stability and potency on human receptors are insufficient
Solution Approach 1:
The patent applies composite materials by combining conventional amino acids with non-proteinogenic amino acids (citrulline, mono-iodo-tyrosine, selenocysteine) in a single peptide molecule. This composite approach allows the peptide to maintain synthesizability through standard solid-phase methods while incorporating specialized residues that enhance stability and human receptor potency.
Data Source
AI summary
The present disclosure describes analog conotoxin peptides of the α-contoxin peptide RgIA. These analog conotoxin peptides block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, inflammatory conditions, inflammation, and/or cancer.